BICO News Feed

Discover the latest news from our business areas.

SCIENION & Cellenion launch the proteoCHIP LF 48, for label-free single-cell proteomics sample preparation on the cellenONE® platform

Share on facebook
Share on twitter
Share on linkedin

Optimized sample preparation workflows facilitate single cell proteomics applications

 

Berlin, Germany, and Lyon, France, September 13, 2022: Today, SCIENION and its subsidiary Cellenion, both companies part of the bioconvergence powerhouse BICO, announced the release of the proteoCHIP LF 48. This chip represents the first commercially available solution enabling reproducible automated miniaturized single- cell proteomics sample preparation and standardized workflow for label-free single-cell mass spectrometry-based proteomics analysis. The proteoCHIP LF 48 was developed in partnership with the Research Institute of Molecular Pathology in Vienna, Austria.

 

Single-cell proteomics is a cutting-edge field of research, as proteins are the main drivers of cellular function. In-depth characterization of individual cells by mass spectrometry (MS)-based proteomics leads to new discoveries about biological processes and allows better understanding of disease mechanisms.

Cellenion has been committed to single-cell isolation and applications in this field since its founding in 2016. The proteoCHIP LF 48, dedicated to label-free workflows, is the second proteoCHIP product brought to the market by Cellenion, after the proteoCHIP 12*16 for multiplex single-cell proteomics workflows launched last year and now used by many leading single-cell proteomics facilities around the world.

 

The proteoCHIP LF 48 is intended to be run in the cellenONE®, Cellenion’s market-leading instrument for single-cell isolation and ultra-small volume dispensing, which enables users to dispense and prepare a single cell in each well of the proteoCHIP, including on-deck cell lysis and protein digestion. The combination of cellenONE and proteoCHIP LF 48 enables all the front end of mass spectrometry on a single instrument with minimal user intervention, allowing preparation of up to 144 single cells per run. This overcomes the limitations of conventional workflows, including lack of automation and multiple manual sample handling steps, which result in important peptide losses throughout the process.

With the combination of both proteoCHIP versions, Cellenion now thus provides researchers with turnkey solutions for single-cell proteomics sample preparation workflows for both multiplex and label-free approaches.

 

“We are delighted to expand our single-cell proteomics offering with the launch of this new proteoCHIP,” said Guilhem Tourniaire, Managing Director at Cellenion. “This product complements our existing capabilities in sample preparation for single-cell proteomics, as it enables an end-to-end workflow for scientists undertaking label-free single cell proteomic studies.”

 

The proteoCHIP LF 48 was launched at the annual symposium of the Austrian Proteomics and Metabolomics Association (APMA) with a symposium focusing on advancements in single-cell proteomics, September 13-15, 2022. The conference was organized by the Research Institute of Molecular Pathology (IMP) in Vienna, Austria.

 

For more information on the proteoCHIP LF 48, please visit:

https://www.cellenion.com/consumables/proteochip-product-line/proteochip-lf48/

 

About SCIENION

Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is an ISO 9001:2015 certified complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Berlin and Dortmund, and has subsidiaries in Phoenix, Arizona (USA), Portsmouth (UK), and Cellenion in Lyon (France).

SCIENION is part of BICO, the world’s leading bioconvergence company, providing technologies, products and services to create the future of health.

 

About Cellenion

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single-cell isolation. Cellenion has developed cellenONE®, a unique technology allowing high-throughput, image-based automated sorting and dispensing of cells onto any substrate. Together with a range of dedicated consumables, cellenONE enables miniaturization of sample preparation protocols. With no dead volumes and outstanding recovery rates, Cellenion’s platform offers unique capacities for applications including single cell transcriptomics, genomics, proteomics, rare cells and cell line development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.

 

About BICO

Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.

Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives. Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com.

 

SCIENION Contact

SCIENION GmbH

Volmerstraße 7b

D-12489 Berlin

Phone: +49 (0)30 – 6392 1700

support@scienion.com

www.scienion.com

 

Cellenion Contact

Cellenion SASU
60 Avenue Rockefeller
Bioserra 2
69008 Lyon
Phone: +33 (0)9 86 48 70 70
E-mail: contact@cellenion.com
www.cellenion.com

 

PR Contact

Almut Gebhard

Phone +49 (0)30 – 6120 1081

Mobile +49 (0)174 3017754

Email: scienion@almutgebhard.de

More news

September 29, 2022 | Dispendix

Exhibiting at ELRIG Drug Discovery

September 14, 2022 | Dispendix

I.DOT HT liquid handler has been nominated for the TechAward 2022!

September 14, 2022 | Bico

Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy

September 14, 2022 | Bico

SCIENION & Cellenion launch the proteoCHIP LF 48, for label-free single-cell proteomics sample preparation on the cellenONE® platform

September 13, 2022 | Cellink

CELLINK is awarded Göteborgs Companipris

September 13, 2022 | Scienion

SCIENION and Cellenion launch the proteoCHIP LF 48, for label-free single-cell proteomics sample preparation on the cellenONE® platform

September 13, 2022 | Cellenion

SCIENION & Cellenion launch the proteoCHIP LF 48, for label-free single-cell proteomics sample preparation on the cellenONE® platform

September 13, 2022 | Bico

3d Bioprinted Human Skin – The Future of Cosmetic Testing​

August 31, 2022 | Dispendix

Press Release: New L version of the I.DOT: Now Available

August 22, 2022 | Cellink

Podcast: 3D Bioprinting – Accelerating Drug Discovery​

August 18, 2022 | Cellink

CELLINK to establish a Centre of Excellence in India with The Indian Institute of Science (IISc)

August 8, 2022 | Cytena

CYTENA launches new generation of B.SIGHT, a fully automated single-cell dispenser for microorganisms

July 28, 2022 | Scienion

SCIENION announces expansion in the UK with the opening of new R&D and manufacturing facilities

July 12, 2022 | Cytena

CYTENA BPS launches C.NEST – a robust, flexible & reliable microbioreactor

July 10, 2022 | Cytena

B2Run Freiburg 2022

July 5, 2022 | Scienion

Highfield Diagnostics and SCIENION Sign Memorandum of Understanding

May 24, 2022 | Cellenion

Breakfast with Cellenion

May 6, 2022 | Cellenion

cellenONE Training & Workshop – June 2022